Alterity Therapeutics Ltd Cash Flow-to-Debt Ratio
Alterity Therapeutics Ltd cash flow-to-debt ratio. Alterity Therapeutics Ltd (ATHE) has a Cash Flow-to-Debt Ratio of -3.88x as of June 2026, meaning its operating cash flow of $-12.80 Million could theoretically repay -4% of its total liabilities ($3.29 Million) in one year. See ATHE financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Alterity Therapeutics Ltd (2002–2026)
Cash flow-to-debt ratio of Alterity Therapeutics Ltd from 2002 to 2026. Historical debt coverage capacity for Alterity Therapeutics Ltd across 25 annual periods. Check total reinvestment intensity of Alterity Therapeutics Ltd to assess the company's total reinvestment commitment from operating cash flow.
Alterity Therapeutics Ltd Cash Flow-to-Debt Ratio by Year (2002–2026)
Alterity Therapeutics Ltd cash flow-to-debt ratio by year from 2002 to 2026. Year-by-year debt coverage analysis for Alterity Therapeutics Ltd. For the full cash flow conversion analysis, see Alterity Therapeutics Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -6.69x | $-22.03 Million | $3.29 Million | ▼ -111.6% |
| 2025 | -3.16x | $-11.45 Million | $3.62 Million | ▼ -36.0% |
| 2024 | -2.32x | $-12.61 Million | $5.43 Million | ▲ +47.8% |
| 2023 | -4.45x | $-20.04 Million | $4.50 Million | ▼ -112.5% |
| 2022 | -2.09x | $-12.34 Million | $5.89 Million | ▲ +62.4% |
| 2021 | -5.56x | $-17.33 Million | $3.12 Million | ▼ -62.6% |
| 2020 | -3.42x | $-9.43 Million | $2.76 Million | ▲ +17.8% |
| 2019 | -4.16x | $-13.95 Million | $3.36 Million | ▼ -76.1% |
| 2018 | -2.36x | $-6.25 Million | $2.64 Million | ▲ +36.0% |
| 2017 | -3.69x | $-5.87 Million | $1.59 Million | ▼ -17.2% |
| 2016 | -3.15x | $-7.42 Million | $2.36 Million | ▲ +21.2% |
| 2015 | -4.00x | $-10.87 Million | $2.72 Million | ▼ -14.6% |
| 2014 | -3.49x | $-13.79 Million | $3.95 Million | ▼ -35.9% |
| 2013 | -2.57x | $-7.95 Million | $3.10 Million | ▲ +35.6% |
| 2012 | -3.98x | $-6.85 Million | $1.72 Million | ▼ -81.8% |
| 2011 | -2.19x | $-4.56 Million | $2.08 Million | ▲ +26.8% |
| 2010 | -3.00x | $-4.71 Million | $1.57 Million | ▲ +63.7% |
| 2009 | -8.25x | $-6.99 Million | $847.43K | ▼ -61.0% |
| 2008 | -5.13x | $-9.41 Million | $1.84 Million | ▼ -17.6% |
| 2007 | -4.36x | $-9.20 Million | $2.11 Million | ▲ +36.7% |
| 2006 | -6.89x | $-11.66 Million | $1.69 Million | ▼ -62.5% |
| 2005 | -4.24x | $-11.37 Million | $2.68 Million | ▼ -115.0% |
| 2004 | -1.97x | $-5.31 Million | $2.70 Million | ▲ +68.9% |
| 2003 | -6.34x | $-3.58 Million | $564.54K | ▼ -53.6% |
| 2002 | -4.13x | $-3.77 Million | $912.82K | — |